Fu et al. [19] predicted that IGF1R is the main target of baicalin against epilepsy and verified through in vivo and in vitro experiments that baicalin inhibits IGF1R, thereby alleviating the symptoms of epilepsy. Here, IGF1R is linked to epilepsy.